From the Turkish Doctor: Drug that Destroys Cancerous Tissue

Miraculous Drug From Turkish Doctor: Destroyed Cancerous Tissue With The Liquid It Developed

  Prof. Dr. Rahmi Öklü has developed a new drug for cancer. This drug, injected directly into the tumor area, enables cancerous cells to be destroyed and prevent their reproduction. The drug, which also caught Harvard's attention, seems to be a weapon against cancer.

  The drug, which is easy to use and surpasses traditional methods in terms of effect, remains in that area for a while after destroying the tumor area. Thus, the reproduction of tumor cells is prevented.

  Making statements about the drug he developed, the scientist says that what is necessary for the administration of the drug is a syringe and an ultrasound device. Expressing that the drug he developed saves from all the side effects caused by chemotherapy, Rahmi Öklü says that high doses of drugs are used in traditional treatments, but this drug called "ionic fluid" does not need a high dose. The drug developed by the Turkish scientist has attracted the attention of the medical world.

The drug of the Turkish scientist also affected Harvard University

  The drug developed by Rahmi Öklü settles in the tumor area for at least 28 days. In the process, the drug not only destroys the tumor area, but also prevents the reproduction of tumor cells. This prevents the cancer from recurring. The scientist said the following about the drug he developed:

  "You can inject this under ultrasound. No fancy, expensive equipment, setup, no materials. Only ultrasound and needles are needed. Another effect is that high levels of T cells, which are important cells of the immune system, come to the treatment areas. This is also important for doing immunotherapy. It provides an excellent time. Today, we will be able to increase the insufficient effectiveness of immunotherapy for solid tumors with this method. "

  Prof. Dr. The cancer drug developed by Rahmi Öklü was announced on the cover of the medical journal "Science Translational Medicine" published on February 10. Harvard University has also been affected by this drug. Updating the university's website, the officials launched Öklü's drug as "an important development in the fight against cancer".